Oncology Key lessons from EHA 2026: Translating evidence into impact Across four days in Sweden, EHA 2026 offered a clear view of the future of blood cancer care.
Oncology Expanding the haematology toolkit: Insights and operational ... With over 8,200 abstracts accepted, ASH 2025 showcased breakthroughs in sickle cell disease, platelet disorders, and next-generation cell therapies.
Oncology Targeting blood cancers with high unmet need When it comes to myeloid malignancies such as acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), treatment progress has been slow.
Oncology Breaking barriers to CAR T-cell therapy: The vision for expa... Live from ASCO 2025: Prof. Dr Jason Westin discusses CAR-T Vision, patient access, and the push to expand therapy reach in rare blood cancers.
Oncology ASCO 2024: Emphasising the art and science behind enhanced c... The term “practice-changing” is often used when scientific advances promise to shift traditional treatment paradigms.
Oncology Warning signs for CAR-T after secondary cancer cases CAR-T treatments emerged as a major success for the pharma industry when first approved in 2017, but this has been muddied by concerns over secondary malignancies.
News Ex-BioNTech execs launch 'AI-native' cancer company Two senior executives formerly at BioNTech have launched a new biotech, Bios Life, that they call "an AI-native cancer surveillance company."
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
